A mitochondrial basis for Huntington's disease: therapeutic prospects (Q38174451)

30 August 2017

title

A mitochondrial basis for Huntington's disease: therapeutic prospects (English)

1 reference

30 August 2017

0 references

J Chakraborty

1

1 reference

30 August 2017

U Rajamma

series ordinal

2

1 reference

30 August 2017

K P Mohanakumar

series ordinal

3

1 reference

30 August 2017

publication date

29 December 2013

1 reference

Molecular and Cellular Biochemistry

30 August 2017

published in

1 reference

30 August 2017

volume

389

1 reference

30 August 2017

issue

1-2

1 reference

30 August 2017

page(s)

277-291

1 reference

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Widespread expression of Huntington's disease gene (IT15) protein product

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Transcriptional abnormalities in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mutant huntingtin affects endocytosis in striatal cells by altering the binding of AP-2 to membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

A stress sensitive ER membrane-association domain in Huntingtin protein defines a potential role for Huntingtin in the regulation of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitochondrial permeability transition in neuronal damage promoted by Ca2 and respiratory chain complex II inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

3-nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Biochemical abnormalities and excitotoxicity in Huntington's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitochondrial defect in Huntington's disease caudate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Complex I defect in muscle from patients with Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Allocortical involvement in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Impaired PGC-1alpha function in muscle in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Ca2 -induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitochondrial calcium, oxidative stress and apoptosis in a neurodegenerative disease model induced by 3-nitropropionic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Loss of MARCH5 mitochondrial E3 ubiquitin ligase induces cellular senescence through dynamin-related protein 1 and mitofusin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

The SUMO protease SENP5 is required to maintain mitochondrial morphology and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

S-nitrosylation of Drp1 links excessive mitochondrial fission to neuronal injury in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Effects of overexpression of huntingtin proteins on mitochondrial integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Disruption of mitochondrial DNA replication in Drosophila increases mitochondrial fast axonal transport in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Axonal mitochondrial transport and potential are correlated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

The axonal transport of mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

The axonal transport of mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

The Miro GTPases: at the heart of the mitochondrial transport machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

GTPase dependent recruitment of Grif-1 by Miro1 regulates mitochondrial trafficking in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Syntabulin is a microtubule-associated protein implicated in syntaxin transport in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

KIF5B motor adaptor syntabulin maintains synaptic transmission in sympathetic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Control of mitochondrial transport and localization in neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Voltage-dependent anion-selective channel (VDAC) interacts with the dynein light chain Tctex1 and the heat-shock protein PBP74

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Myelination and axonal electrical activity modulate the distribution and motility of mitochondria at CNS nodes of Ranvier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Nitric oxide inhibits mitochondrial movement in forebrain neurons associated with disruption of mitochondrial membrane potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Nitric oxide impairs mitochondrial movement in cortical neurons during hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Activity-dependent regulation of mitochondrial motility by calcium and Na/K-ATPase at nodes of Ranvier of myelinated nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Shaping the role of mitochondria in the pathogenesis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mutant huntingtin enhances excitotoxic cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Inefficient degradation of truncated polyglutamine proteins by the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Morphometric analysis of Huntington's disease neurodegeneration in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Glutathione peroxidase activity is neuroprotective in models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Cytochrome C and caspase-9 expression in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

3-Nitropropionic acid induces autophagy by forming mitochondrial permeability transition pores rather than activating the mitochondrial fission pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitochondria as a target for neurotoxins and neuroprotective agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Evaluation of Dimebon in cellular model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Increased levels of oxidatively damaged DNA induced by chromium(III) and H2O2: protection by melatonin and related molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Y cultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Melatonin reduces induction of Bax, caspase and cell death in methamphetamine-treated human neuroblastoma SH-SY5Y cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Delayed onset of the diurnal melatonin rise in patients with Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Neuroprotective effect of carvedilol and melatonin on 3-nitropropionic acid-induced neurotoxicity in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca(2 )-mediated permeability transition and beyond in rat brain astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Structure-antioxidant activity relationships of flavonoids and phenolic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

<i>N</i>-Acetylcysteine Reverses Mitochondrial Dysfunctions and Behavioral Abnormalities in 3-Nitropropionic Acid-Induced Huntington’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

N-acetylcysteine elicited increase in cytochrome c oxidase activity in mice synaptic mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Lipoic acid improves survival in transgenic mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Paroxetine retards disease onset and progression in Huntingtin mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

A controlled trial of remacemide hydrochloride in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Amantadine in Huntington's disease: open-label video-blinded study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

A randomized trial of amantadine in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Effects of memantine on mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Aspirin induces apoptosis through the inhibition of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Unchanged mitochondrial organization and compartmentation of high-energy phosphates in creatine-deficient GAMT-/- mouse hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Retinal ganglion cell survival is enhanced by gabapentin-lactam in vitro: evidence for involvement of mitochondrial KATP channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Lamotrigine inhibition of rotenone- or 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Efficacy of levetiracetam in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Off label use of lithium in the treatment of Huntington's disease: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

In vitro effects of lithium and nickel at different levels on Neuro-2a mouse neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Minocycline in phenotypic models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Neuroprotection in Huntington's disease: a 2-year study on minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Inhibitory modulation of the mitochondrial permeability transition by minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Impairment of mitochondrial function by minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha -lipoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11010-013-1951-9

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

21 January 2018

1 reference

12 December 2020

Glutamate decreases mitochondrial size and movement in primary forebrain neurons.

1 reference

12 December 2020

Mitochondrial NAD -linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease.

1 reference

12 December 2020

Tissue distribution of quercetin in rats and pigs

1 reference

12 December 2020

Systemic approaches to modifying quinolinic acid striatal lesions in rats

1 reference

12 December 2020

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

1 reference

12 December 2020

Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease

1 reference

12 December 2020

Mitochondrial organization and motility probed by two-photon microscopy in cultured mouse brainstem neurons.

1 reference

12 December 2020

Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

1 reference

12 December 2020

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

1 reference

12 December 2020

Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission

1 reference

12 December 2020

The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.

1 reference

12 December 2020

Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats

1 reference

12 December 2020

Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin

1 reference

12 December 2020

Mitochondria frozen with trehalose retain a number of biological functions and preserve outer membrane integrity

1 reference

12 December 2020

Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats

1 reference

12 December 2020

The role of melatonin in sleep disturbances in end-stage Huntington's disease

1 reference

12 December 2020

Rapamycin Modulates Markers of Mitochondrial Biogenesis and Fatty Acid Oxidation in the Adipose Tissue of db/db Mice

1 reference

12 December 2020

Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's Disease.

1 reference

12 December 2020

The rise and fall of Dimebon

1 reference

12 December 2020

3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin.

1 reference

12 December 2020

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

1 reference

12 December 2020

N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson's disease

1 reference

12 December 2020

10.1007/S11010-013-1951-9

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1010936262

0 references

1 reference